LI-RADS CT/MRI Nonradiation Treatment Response Assessment Version 2024 for Detecting Local Recurrence of Surgically Resected Hepatocellular Carcinoma

Sung-Hua Chiu, Luke Yoon, Stephan Altmayer, Daniel Delitto, Aya Kamaya, Justin R. Tse

原始摘要（英文原文）· Original abstract

Background: LI-RADS CT/MRI Nonradiation Treatment Response Assessment (TRA) version 2024 (v2024) specifies that the updated algorithm may be applied for evaluating the surgical margin after hepatocellular carcinoma (HCC) resection.

读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

LR-TR viable as an early imaging indicator of local recurrence after radiofrequency ablation for hepatocellular carcinoma: a longitudinal assessment using LI-RADS nonradiation TRA version 2024.
Contrast-enhanced ultrasound LI-RADS nonradiation treatment response assessment: applications, challenges, and future directions
<scp>MRI</scp> ‐Based Score to Predict Retreatment Response for Viable Hepatocellular Carcinomas After Transarterial Chemoembolization
Evaluating Accuracy of LI-RADS Nonradiation Treatment Response Algorithm v2024 and Ancillary Features at Hepatobiliary MRI versus CT
Preoperative Gd-EOB-DTPA-enhanced MRI may help predict macrotrabecular-massive subtype and postoperative recurrence in small hepatocellular carcinoma (≤ 3 cm).